Regeneron Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 11/29/2023
Regeneron Pharmaceuticals Inc Stock Forecast and Price Target
The average target price for Regeneron Pharmaceuticals Inc's stock set by nine renowned analysts in recent months is $914.00, representing a potential upside of approximately 14.09% from its last closing price if met by 2024. This estimation is based on a high estimate of $1066.00 and a low estimate of $680.00. If you want to invest in REGN stock, you might also want to take a look at how its competitors are doing.
14.09% Upside
Regeneron Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Regeneron Pharmaceuticals Inc's Price has seen an increase, rising from $376.22 to $685.95. This represents a growth of 82.33%. Analysts predict that Regeneron Pharmaceuticals Inc's Fair Value will increase in the upcoming year, reaching $700.43. This would represent an increase of 2.11%. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Fair Value will fall to $614.12– a 10.47% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
16
|
$591.60 | Buy/Sell | $594.01 | 9.87% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$151.63 | Buy/Sell | $176.14 | 13.43% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$100.18 | Buy/Sell | $123.75 | 24.78% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$29.69 | Buy/Sell | $40.55 | 26.31% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$48.92 | Buy/Sell | $64.26 | 25.72% |
Regeneron Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Regeneron Pharmaceuticals Inc's Revenue has seen an increase, rising from $6.56B to $12.17B. This represents a growth of 85.63%. Analysts predict that Regeneron Pharmaceuticals Inc's Revenue will increase in the upcoming year, reaching $12.43B. This would represent an increase of 2.08%. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Revenue will fall to $11.25B– a 7.55% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
15
|
$347.04 | Buy/Sell | $395.90 | 12.38% |
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$176.97 | Buy/Sell | $217.57 | 18.66% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$161.36 | Buy/Sell | $245.24 | 42.54% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$36.34 | Buy/Sell | $45.50 | 22.45% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.14 | Buy/Sell | $11.74 | 25.82% |
| UTHR Stock Forecast | United Therapeutics Corp | Outperform |
12
|
$230.39 | Buy/Sell | $278.82 | 30.21% |
Regeneron Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
Regeneron Pharmaceuticals Inc's Free Cash Flow has grown in the last three years, jumping from $2.00B to $4.46B – an increase of 123.11%. In the next year, analysts predict that Free Cash Flow will reach $5.57B – an increase of 24.73%. For the next eight years, the forecast is for Free Cash Flow to grow by 15.75%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$48.34 | Buy/Sell | $51.20 | 24.12% |
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$39.46 | Buy/Sell | $49.29 | 21.64% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$122.71 | Buy/Sell | $145.00 | 22.24% |
Regeneron Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Net Income for Regeneron Pharmaceuticals Inc has grown by 105.05%, going from $2.12B to $4.34B. In the coming year, analysts are expecting an increase in Net Income, predicting it will reach $5.24B – an increase of 20.85%. Over the next eight years, experts anticipate that Net Income growth for Regeneron Pharmaceuticals Inc will be 7.92%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$190.94 | Buy/Sell | $170.08 | 73.09% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$16.60 | Buy/Sell | $37.00 | 34.04% |
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$31.22 | Buy/Sell | $61.75 | 92.18% |
Regeneron Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Regeneron Pharmaceuticals Inc's EBITDA has increased by 117.30%, going from $2.46B to $5.34B. In the next year, analysts are expecting an increase in EBITDA, predicting it will reach $6.59B – an increase of 23.48%. The Regeneron Pharmaceuticals Inc forecast is for EBITDA to reach $5.97B or grow by 11.80%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$54.41 | Buy/Sell | $69.00 | 21.30% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$25.45 | Buy/Sell | $0.00 | 41.45% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£12.38 | Buy/Sell | £3.79 | 134.25% |
Regeneron Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Regeneron Pharmaceuticals Inc's EBIT has grown, increasing from $2.25B to $4.99B – an increase of 122.45%. For next year, the 5 analysts predict EBIT of $5.25B, which would mean an increase of 5.13%. In 2030, the professionals' prediction is that REGN's EBIT will decrease by 11.37%, reaching $4.43B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$12.63 | Buy/Sell | $26.83 | 90.02% |
| CPRX Stock Forecast | Catalyst Pharmaceuticals | Outperform |
16
|
$14.21 | Buy/Sell | $23.30 | 75.93% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Outperform |
14
|
$9.68 | Buy/Sell | $17.40 | 106.61% |
Regeneron Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Regeneron Pharmaceuticals Inc's EPS has seen an increase, rising from $24.67 to $44.98. This represents a growth of 82.33%. Analysts predict that Regeneron Pharmaceuticals Inc's EPS will increase in the upcoming year, reaching $45.93. This would represent an increase of 2.11%. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's EPS will fall to $40.27– a 10.47% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$26.97 | Buy/Sell | $41.00 | 53.87% |
| ARPO Stock Forecast | Aerpio Pharmaceuticals | - |
6
|
$30.30 | Buy/Sell | $0.00 | -100.00% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$27.50 | Buy/Sell | $49.11 | 81.82% |
Site Navigation
.jpg)